Group 1 - The core viewpoint of the news is that Panu Biotechnology (Tianjin) Co., Ltd. has completed an angel round of financing amounting to several tens of millions of RMB, with participation from investors such as Yuanxi Haihe Fund, Ruijiu Venture Capital, and Haihe Industrial Fund [1] - Panu Biotechnology focuses on the development and application of tumor vaccines, specifically the PRBT001 injection, which is a novel mRNA therapeutic vaccine for prostate cancer [1] - The core technology of the vaccine, including mRNA sequences, delivery systems, and production processes, has established a complete global patent asset, laying a solid foundation for the product's international development [1] Group 2 - The PRBT001 product has completed comprehensive preclinical evaluations and aims to provide a new and effective immunotherapy option for prostate cancer patients worldwide [1]
【投融资动态】磐如生物天使轮融资，融资额数千万人民币，投资方为元希海河基金、瑞久创投等
Sou Hu Cai Jing·2026-01-13 11:34